CVKD
HEALTHCARECadrenal Therapeutics Inc
$6.17-0.15 (-2.37%)PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving CVKD Today?
No stock-specific AI insight has been generated for CVKD yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.21$16.25
$6.17
Fundamentals
Market Cap$19M
P/E Ratio—
EPS$-6.64
Dividend Yield—
Dividend / Share—
ROE-2.6%
Profit Margin—
Debt / Equity—
Trading
Volume91K
Avg Volume (10D)—
Shares Outstanding3.1M
CVKD News
20 articles- CVKD: Designing Phase 3 Trial for CAD-1005 in HITYahoo Finance·May 8, 2026
- Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDAYahoo Finance·May 7, 2026
- Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)Yahoo Finance·Apr 30, 2026
- Analysts Adjust Cadrenal Therapeutics, Inc. (CVKD) Valuation After Including CAD-1005 ProgramYahoo Finance·Apr 21, 2026
- CVKD: Results Show 12-LOX Inhibition Targets Inflammation from Obesity and Type 2 DiabetesYahoo Finance·Apr 8, 2026
- Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA MeetingYahoo Finance·Mar 31, 2026
- OTC Markets Hosts Virtual Investor Presentation with Quang Pham, Chairman and CEO of Cadrenal Therapeutics, and David Bautz, PhD, Senior Analyst at Zacks SCRYahoo Finance·Mar 20, 2026
- Life Sciences Virtual Investor Forum Presentations Now Available for Online ViewingYahoo Finance·Mar 13, 2026
- Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 DiabetesYahoo Finance·Mar 12, 2026
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12thYahoo Finance·Mar 10, 2026
- Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform ExpansionYahoo Finance·Mar 2, 2026
- CVKD: Phase 2 HIT Results Show Encouraging Reduction in Thrombotic EventsYahoo Finance·Feb 25, 2026
- Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical AdvancementYahoo Finance·Feb 24, 2026
- CVKD: Acquires 12-LOX Inhibitor for the Treatment of Heparin-Induced Thrombocytopenia (HIT)Yahoo Finance·Feb 20, 2026
- Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX InhibitorYahoo Finance·Jan 12, 2026
- Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response SystemYahoo Finance·Dec 30, 2025
- Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up OnYahoo Finance·Dec 29, 2025
- Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026Yahoo Finance·Dec 17, 2025
- Cadrenal's Quiet Expansion Play Is Starting to Get LoudYahoo Finance·Dec 12, 2025
- Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion MarketYahoo Finance·Dec 12, 2025
All 20 articles loaded
Price Data
Open$6.88
Previous Close$6.32
Day High$7.27
Day Low$6.16
52 Week High$16.25
52 Week Low$4.21
52-Week Range
$4.21$16.25
$6.17
Fundamentals
Market Cap$19M
P/E Ratio—
EPS$-6.64
Dividend Yield—
Dividend / Share—
ROE-2.6%
Profit Margin—
Debt / Equity—
Trading
Volume91K
Avg Volume (10D)—
Shares Outstanding3.1M
About Cadrenal Therapeutics Inc
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for renal diseases and kidney-related disorders. Leveraging proprietary drug platforms, the company aims to address significant unmet medical needs with its candidates advancing through rigorous clinical trials. With a strong focus on scientific excellence and a commitment to patients, Cadrenal is well-positioned to make a transformative impact on renal health, highlighting substantial growth potential within the dynamic biopharmaceutical market.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—